One arm of the phase II I-SPY2 platform trial compared pembrolizumab plus neoadjuvant chemotherapy (NACT) to NACT alone in stage II/III HER2− BC patients (HR+ n = 40). This evidence concerns the gene ERBB2 and breast cancer.